Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Assets (2020 - 2025)

Foghorn Therapeutics has reported Current Assets over the past 6 years, most recently at $163.2 million for Q4 2025.

  • Quarterly results put Current Assets at $163.2 million for Q4 2025, down 34.6% from a year ago — trailing twelve months through Dec 2025 was $163.2 million (down 34.6% YoY), and the annual figure for FY2025 was $163.2 million, down 34.6%.
  • Current Assets for Q4 2025 was $163.2 million at Foghorn Therapeutics, down from $184.1 million in the prior quarter.
  • Over the last five years, Current Assets for FHTX hit a ceiling of $459.6 million in Q4 2021 and a floor of $124.0 million in Q3 2021.
  • Median Current Assets over the past 5 years was $257.5 million (2023), compared with a mean of $268.4 million.
  • Biggest five-year swings in Current Assets: surged 204.76% in 2022 and later crashed 34.6% in 2025.
  • Foghorn Therapeutics' Current Assets stood at $459.6 million in 2021, then fell by 23.54% to $351.4 million in 2022, then crashed by 31.65% to $240.2 million in 2023, then rose by 3.92% to $249.6 million in 2024, then crashed by 34.6% to $163.2 million in 2025.
  • The last three reported values for Current Assets were $163.2 million (Q4 2025), $184.1 million (Q3 2025), and $203.8 million (Q2 2025) per Business Quant data.